Gerresheimer, the German supplier of packaging systems for the food and drug industries, experienced a significant boost in its shares following a better-than-expected revenue outlook for 2025. The company also announced securing new orders related to weight-loss drugs last year.
Positive Growth Projections
With an impressive revenue growth expected between 5% and 10% for 2024, along with adjusted earnings-per-share growth of 8% to 12%, Gerresheimer is on a path towards success. Looking ahead to 2025, the company anticipates even more promising figures, including revenue growth accelerating to between 10% and 15%, with adjusted EPS forecasted to increase by more than 10%.
Analysts’ Forecasts
According to consensus estimates, analysts are predicting revenue growth of 6.9% and adjusted EPS of EUR5.17 in 2024. For 2025, revenue growth is expected to reach 11%, with adjusted EPS projected to be EUR6.72.
Expansion and Strong Order Intake
Gerresheimer is taking proactive steps to meet the growing demand, with plans to expand production capacity in response to a continuous stream of new orders. These orders include syringes, pens, and auto-injectors for GLP-1 drugs, a category encompassing diabetes and anti-obesity medications that are currently in high demand.
Solid Performance in Q4
For the fourth quarter, Gerresheimer reported an adjusted net profit of EUR52.7 million, marking an 8.2% increase compared to the same period the previous year. Total revenue reached EUR545.2 million, up by 3.1%, driven by robust demand in the plastics and devices division, which benefited from the pharmaceutical industry’s strong performance.
With a clear vision for growth and an unwavering commitment to meeting market demands, Gerresheimer is positioning itself as a key player in the industry’s landscape.
